- Novel class of antibiotics
- Bactericidal activity demonstrated in vitro and in vivo against broad range of Gram-negative bacteria, including multidrug-resistant strains
Allschwil,
Dr.
The antibiotics were developed within Spexis’ Outer Membrane Protein Targeting Antibiotics (OMPTA) program and selectively disrupt the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. This results in a loss of the integrity of the outer cell membrane, intracellular accumulation of lipopolysaccharides and killing of the bacteria. Activity has been shown in vitro and in vivo against Enterobacteriaceae such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy. The program was funded in part by CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator).2 This underscores the potential of this novel class of antibiotics. CARB-X is a global non-profit partnership dedicated to supporting early-stage antibacterial research and development, to address the rising threat of drug-resistant bacteria.
Basilea is acquiring all program compounds, know-how and intellectual property and is paying Spexis up to a total of
About multidrug-resistant Gram-negative bacteria
Infections by multidrug-resistant Gram-negative bacteria (GNB) are a major challenge for healthcare professionals. Due to an additional outer cell membrane compared to Gram-positive bacteria, it is more difficult for antibiotics to get into the cell. In addition, this outer membrane carries lipopolysaccharides/endotoxins which induce inflammation and play an important amplifying role in the pathogenesis of infections by GNB and are therefore considered an important virulence factor. Moreover, GNB can acquire resistance to several classes of antibiotics such as carbapenems, fluoroquinolones, tetracyclines and earlier-generation cephalosporins, making infections with GNBs particularly difficult to treat. In 2017, the
About Basilea
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning
For further information, please contact:
Head of Hegenheimermattweg 167b 4123 Allschwil | |
Phone | +41 61 606 1102 |
media_relations@basilea.com investor_relations@basilea.com |
This press release can be downloaded from www.basilea.com.
References
M. Schuster , E. Brabet, K. K. Oi et al. Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae. Science Advances 2023 (9), eadg3683- Research reported in this press release is supported by CARB-X. CARB-X’s funding for this project is provided in part with federal funds from the
US Department of Health and Human Services ; Administration for Strategic Preparedness and Response;Biomedical Advanced Research and Development Authority ; under agreement number 75A50122C00028; and by awards from Wellcome (WT224842) and Germany’sFederal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. - https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (Accessed:
January 14, 2024 )
Attachment
- Press release (PDF)
Source:
2024 GlobeNewswire, Inc., source